Corporate Profile

AUM Biosciences is a global clinical-stage biotech company, focused on discovering, developing and advancing a pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance. The company’s lead program, AUM has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotecl models, and has contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM001, is a best-in-class MNK inhibitor targeting MSS Colorectal Cancer and many other tumor types by selective inhibition of oncogenic protein translation. The company has a portfolio of assets with clear de-risking mechanisms put in place.

Events

29 – 31st March 2022

Next Generation Kinase Inhibitor Summit 2022, Boston

Read more..

18 November 2021

Bio Connections Australia 2021, Melbourne

Read more..

25 August 2021

PI3K Pathways Virtual Summit 2021, Massachusetts

Read more..

May 27, 2021

IQVIA Biotech Industry Opportunities Conference

Read more..

Press Release & Media

     August 18, 2022: AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene

Read more..

     June 07, 2022: AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer

Read more..

     May 17, 2022: AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development

Read more..